EUCTR2008-004457-15-CZ进行中（未招募）不适用
Cilengitide in subjects with newly diagnosed glioblastoma multiforme and unmethylated MGMT gene promoter - a multicenter, open-label Phase II study, investigating two cilengitide regimens in combination with standard treatment (temozolomide with concomitant radiation therapy, followed by temozolomide maintenance therapy) - CORE. - CORE
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Merck KGaA
- 入组人数
- 260
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written informed consent obtained before undergoing any study-related activities.
- •2. Newly diagnosed histologically proven supratentorial GBM (World Health Organization [WHO] Grade IV, including GBM subtypes, e.g. gliosarcoma). The histological diagnosis must be obtained from a neurosurgical resection of the tumor or by an open biopsy (stereotactic biopsy not allowed).
- •3. Tumor tissue specimens from the GBM surgery or open biopsy (formalin-fixed paraffin-embedded [FFPE] block) must be available for MGMT gene promoter status analysis and central pathology review.
- •4. Proven unmethylated MGMT gene promoter status (i.e. cut-off ratio <1 by means of applied test to determine MGMT gene promoter status)
- •5. Males or females =18 years of age.
- •6. Interval of =2 weeks but =7 weeks after surgery or biopsy before first administration of study treatment.
- •7. Available post-operative Gd-MRI performed within <48 hours after surgery (in case that it was not possible to obtain a Gd-MRI within <48 hours post surgery, a Gd-MRI is to be performed prior to randomization).
- •8. Stable or decreasing dose of steroids for ‡5 days prior to randomization.
- •9. ECOG PS of 0-1.
- •10. Meets 1 of the following RPA classifications:
- •Class III (Age <50 years and ECOG PS 0).
- •Class IV (meeting one of the following criteria: a) Age <50 years and ECOG PS 1 or b) Age =50 years, underwent prior partial or total tumor resection, Mini Mental State Examination [MMSE] =27).
- •Class V (meeting one of the following criteria: a) Age =50 years and underwent prior partial or total tumor resection, MMSE <27 or
- •b) Age =50 years and underwent prior tumor biopsy only).
- •11. Laboratory values (within 2 week prior to randomization):
- •Absolute neutrophil count ‡1500/mm3.
- •Platelets ‡100,000/mm3.
- •Creatinine £1.5 x upper limit of normal (ULN) or creatinine clearance rate ‡60 mL/min.
- •Prothrombin time (PT) international normalized ratio (INR) within normal limits and partial thromboplastin time (PTT) below upper limit of normal.
- •Hemoglobin ‡10 g/dL.
- •Total bilirubin £1.5 x the ULN.
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) £2.5 x ULN (except when attributable to anticonvulsants).
- •Alkaline phosphatase £2.5 x ULN.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Prior chemotherapy within the last 5 years.
- •2. Prior RTX of the head (except for low dose radiotherapy for Tinea capitis).
- •3. Receiving concurrent investigational agents or has received an investigational agent within the past 30 days prior to the first dose of cilengitide.
- •4. Prior systemic antiangiogenic therapy.
- •5. Placement of Gliadel® wafer at surgery.
- •6. Planned major surgery for other diseases (e.g. dental extraction).
- •7. History of recent peptic ulcer disease (endoscopically proven gastric ulcer, duodenal ulcer, or esophageal ulcer) within 6 months of enrollment.
- •8. History of malignancy. Subjects with curatively treated cervical carcinoma in situ or basal cell carcinoma of the skin, or subjects who have been free of other malignancies for ‡5 years are eligible for this study.
- •9. History of coagulation disorder associated with bleeding or recurrent thrombotic events.
- •10. Clinically manifest myocardial insufficiency (New York Heart Association [NYHA] III, IV) or history of myocardial infarction during the past 6 months; or uncontrolled arterial hypertension.
- •11. Inability to undergo Gd-MRI.
- •12. Concurrent illness, including severe infection, which may jeopardize the ability of the subject to receive the procedures outlined in this protocol with reasonable safety.
- •13. Subject is pregnant (positive serum beta human chorionic gonadotropin [b-HCG] test at screening) or is currently breast-feeding, or has the potential and anticipates becoming pregnant/ impregnating their partner during the study or within 6 months after study participation, or subject does not agree to follow acceptable methods of birth control, such as hormonal contraception, intra-uterine pessar, condoms or sterilization, to avoid conception during the study and for at least 6 months after receiving the last dose of study treatment.
- •14. Current alcohol dependence or drug abuse.
- •15. Known hypersensitivity to the study treatment.
- •16. Legal incapacity or limited legal capacity.
- •17. Presence of any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
研究者
相似试验
进行中（未招募）
1 期
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status (CENTRIC)ewly diagnosed, histologically proven GBM with proven methylated MGMT gene promoter statusMedDRA version: 15.1Level: PTClassification code 10018337Term: Glioblastoma multiformeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2007-004344-78-BEMerck KGaA2,000
进行中（未招募）
1 期
Cilengitide in subjects with newly diagnosed glioblastoma multiforme and methylated MGMT gene promoter – a multicenter, open-label, controlled Phase III study, testing cilengitide in combination with standard treatment (temozolomide with concomitant radiation therapy, followed by temozolomide maintenance therapy) versus standard treatment alone. - CENTRICEUCTR2007-004344-78-FRMerck KGaA545
进行中（未招募）
不适用
Cilengitide in subjects with newly diagnosed glioblastoma multiforme and methylated MGMT gene promoter – a multicenter, open-label, controlled Phase III study, testing cilengitide in combination with standard treatment (temozolomide with concomitant radiation therapy, followed by temozolomide maintenance therapy) versus standard treatment alone. - CENTRICewly diagnosed, histologically proven GBM with proven methylated MGMT gene promoter statusMedDRA version: 9.1Level: LLTClassification code 10018337Term: Glioblastoma multiformeEUCTR2007-004344-78-NLMerck KGaA1,400
进行中（未招募）
不适用
Cilengitide in subjects with newly diagnosed glioblastoma multiforme and methylated MGMT gene promoter – a multicenter, open-label, controlled Phase III study, testing cilengitide in combination with standard treatment (temozolomide with concomitant radiation therapy, followed by temozolomide maintenance therapy) versus standard treatment alone. - CENTRICewly diagnosed, histologically proven GBM with proven methylated MGMT gene promoter statusMedDRA version: 9.1Level: LLTClassification code 10018337Term: Glioblastoma multiformeEUCTR2007-004344-78-CZMerck KGaA2,000
进行中（未招募）
不适用
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status (CENTRIC)ewly diagnosed, histologically proven GBM with proven methylated MGMT gene promoter statusMedDRA version: 14.1Level: PTClassification code 10018337Term: Glioblastoma multiformeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2007-004344-78-ATMerck KGaA2,000